BIOMAT Database Logo BIOMAT Database Logo

A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. 1992

C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905.

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10(6) U/m2 three times weekly. Toxicity was substantial and necessitated at least a 50% dose reduction in all but five patients during the first 1-2 months of therapy. No responses were observed in patients with bone metastases, but complete and partial regression of nodal disease were observed in two patients with extraosseous disease (overall response rate, 5%; 95% confidence interval, 0.64-17.75%). The authors conclude that IFL-RA cannot be recommended at this dose and schedule in patients with advanced prostate cancer, but additional study of its use in patients with nodal disease may be warranted.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
March 2009, The Journal of urology,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
A phase II study of temozolomide in hormone-refractory prostate cancer.
January 2000, Cancer chemotherapy and pharmacology,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma.
February 1986, Journal of interferon research,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
January 1994, Investigational new drugs,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
September 1994, Urology,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
January 1995, Investigational new drugs,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
August 1990, Journal of biological response modifiers,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
September 1993, Cancer,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
A Phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study.
March 1994, Cancer,
C M van Haelst-Pisani, and R L Richardson, and J Su, and J C Buckner, and R G Hahn, and S Frytak, and L K Kvols, and P A Burch
Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial.
January 1985, British journal of cancer,
Copied contents to your clipboard!